Silence Therapeutics Plc - Amer (SLN) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.24

Estimate

-$0.09

Surprise

-166.7%

Score today

4.5/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Silence Therapeutics Plc - Amer (SLN) reported a wider loss than forecast — adjusted EPS of -$0.24 against the -$0.09 estimate (a 166.7% shortfall).

• Silence Therapeutics Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-12
• Silence Therapeutics Q3 EPS $(0.24) Misses $(0.12) Estimate — benzinga, 2026-11-12
• Silence Therapeutics Says Phase 2 SANRECO Data For Divesiran In Polycythemia Vera Accepted For Oral Presentation At ASH — benzinga, 2026-11-12

TrendMatrix currently rates SLN Sell at 4.5/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's -166.7% surprise compares with a -133.5% four-quarter average. Next scheduled report: 2027-03-04.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$19.83

Stop

$19.69

Model outputs from TrendMatrix’s engine as of 2026-11-15 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.23B

P/E (fwd)

-52.2

52-week range

$4.19–$19.86

Off 52-week high

0.2%

RSI (14)

55

Volume vs avg

0.10×

Score today

4.5/10